Hello, everyone, and welcome to another working week, at least for those of you on this side of the pond, where an extended weekend has just ended thanks to a day to reflect on American presidents. Now, though, the daunting routine of meetings, deadlines, and the like has returned. There is no avoiding it, you know? So to cope, yes, we are quickly quaffing the required cups of stimulation and invite you to join us. Meanwhile, here are some tidbits to help you along. Have a smashing day and do keep in touch …
Gilead Sciences agreed to pay Sarepta Therapeutics $125 million for a rare pediatric disease priority review voucher. This is apparently the third voucher that Gilead has bought. Sarepta received its voucher along with regulatory approval of its Exondys 51 drug for Duchenne muscular dystrophy. A company can redeem the voucher when seeking approval for another drug to treat any illness, and the Food and Drug Administration is obligated to review this other drug in six months instead of the standard 10 months.
About the Author Reprints
